TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $2.6667.

TCRX has been the topic of several research reports. HC Wainwright downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Tuesday, September 8th. Lifesci Capital cut TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Wedbush downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research report on Wednesday, September 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Finally, Weiss Ratings cut TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th.

TScan Therapeutics Stock Performance

TCRX opened at $0.32 on Monday. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $21.72 million, a PE ratio of -0.35 and a beta of 1.07. TScan Therapeutics has a 1-year low of $0.31 and a 1-year high of $2.57. The firm has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $0.96.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.88 million. As a group, equities analysts anticipate that TScan Therapeutics will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Panagora Asset Management Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $25,000. Landscape Capital Management L.L.C. bought a new position in TScan Therapeutics in the second quarter valued at approximately $25,000. HRT Financial LP bought a new position in TScan Therapeutics in the fourth quarter valued at approximately $26,000. Public Employees Retirement System of Ohio acquired a new stake in TScan Therapeutics during the 1st quarter worth $28,000. Finally, Boothbay Fund Management LLC grew its holdings in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.